1. Home
  2. SAFE vs CRVS Comparison

SAFE vs CRVS Comparison

Compare SAFE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$16.56

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.87

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
CRVS
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
SAFE
CRVS
Price
$16.56
$14.87
Analyst Decision
Hold
Strong Buy
Analyst Count
10
6
Target Price
$19.00
$30.17
AVG Volume (30 Days)
352.1K
1.5M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
48.04
EPS
0.40
N/A
Revenue
$385,552,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$41.13
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$3.96
52 Week High
$17.16
$26.95

Technical Indicators

Market Signals
Indicator
SAFE
CRVS
Relative Strength Index (RSI) 59.76 57.18
Support Level $14.71 $14.24
Resistance Level N/A $16.85
Average True Range (ATR) 0.45 0.81
MACD 0.03 0.05
Stochastic Oscillator 73.76 56.33

Price Performance

Historical Comparison
SAFE
CRVS

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: